亚虹医药：APL-1401 Ib期临床试验获得积极初步结果

Core Viewpoint - The company announced positive preliminary results from the Phase Ib clinical trial of APL-1401 for the treatment of moderate to severe active ulcerative colitis (UC) [1] Company Summary - APL-1401 is a potent and selective dopamine β-hydroxylase (DBH) inhibitor that increases dopamine (DA) levels and decreases norepinephrine (NE) levels by inhibiting the only catalytic enzyme for the synthesis of NE from DA [1] - The development of APL-1401 is expected to provide new treatment options for UC patients, as there is currently no cure for ulcerative colitis [1] Industry Summary - Ulcerative colitis (UC) currently lacks a cure, highlighting the significance of APL-1401's potential impact on restoring intestinal immune homeostasis [1]